explore -WSS

explore

author：knowledge 2025-08-26 23:47:19 - browse：1138

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

hotspot

WSS

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

UnitedHealth increases loan offers after Change Healthcare outage

Virtual Event: March of the Biosimilars

North Korean leader's powerful sister says warplanes repelled US spy plane

Future doctors should be trained to promote social change

hotspot

explore

focus

Duchenne breakthrough therapy leaves behind pioneering families

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

In age of alternative facts, a scholarly course on calling out crap

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

United colonoscopy coverage change 'may cost lives,' doctors say

Methadone treatment changes are coming. Do they go far enough?

In age of alternative facts, a scholarly course on calling out crap

Methadone treatment changes are coming. Do they go far enough?

Hepatitis C has a cure — but many Americans still lack access to it

California man arrested in connection with serial murders of Mexican strip club workers

knowledge

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

The PBM ad wars are taking over Washington, D.C.

California man arrested in connection with serial murders of Mexican strip club workers

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Asbestos, a deadly carcinogen, banned by EPA

Baby aspirin cuts fat buildup in liver disease patients, in small study

hotspot

hotspot

hotspot

hotspot